Epigenetic test for risk-stratification impacts gastroenterologists' decision making and improves confidence when caring for patients with Barrett's esophagus. BALTIMORE, Oct. 28, 2024 /PRNewswire/ -- Previse, a gastrointestinal health company, today announced the company presented...
Previse Showcases New Data Highlighting Clinical Utility of Esopredict® Barrett's Esophagus Prognostic Test at ACG 2024
Seaking AlphaSeeking Alpha / Seaking Alpha 6 hours ago 1 Views
Comments